急性非复杂性B型主动脉夹层管理与结局的趋势与更新
综述总结急性非复杂性B型主动脉夹层的管理趋势:欧美更新指南推荐对高风险非复杂性病例行胸主动脉腔内修复(TEVAR),国际注册研究显示腔内治疗增加且死亡率下降,但常规TEVAR仍存争议,需整合临床与影像危险因素进行个体化选择,多项随机对照试验正在进行。
要点
- 更新欧美指南推荐对高风险非复杂性B型主动脉夹层行TEVAR,高风险因素包括主动脉直径大、破口大或持续疼痛。
- 国际急性主动脉夹层注册观察显示腔内管理增加且死亡率随时间下降。
- 对所有非复杂性病例常规TEVAR仍有争议,因存在卒中与脊髓缺血等风险,需谨慎选择患者。
核心结论
- 当前证据支持整合临床与影像危险因素的个体化方法,以识别最可能从预先TEVAR获益的患者。
- 对所有非复杂性病例常规使用TEVAR目前仍有争议,因存在卒中和脊髓缺血等风险。
- 正在进行的随机对照试验(包括IMPROVE-AD、SUNDAY和EARNEST)有望提供TEVAR在非复杂性TBAD中风险与获益的关键数据。
研究设计与样本
- 本文为综述,总结急性非复杂性B型主动脉夹层管理与结局的趋势与更新。
主要发现
- 国际急性主动脉夹层注册观察显示向腔内管理显著转变且死亡率随时间下降。
- 急性夹层支架移植物或最佳药物治疗及主动脉夹层支架移植物研究试验提示,预先TEVAR可能通过促进有利的主动脉重塑使某些高风险患者获益。
关键数值与推荐
- 更新美国与欧洲指南推荐对高风险非复杂性病例行胸主动脉腔内修复(TEVAR),高风险特征包括主动脉直径大、破口大或持续疼痛。
临床怎么用
- 当前证据支持整合临床与影像危险因素的个体化方法,以识别最可能从预先TEVAR获益的患者。
- 对所有非复杂性病例常规使用TEVAR目前仍有争议,需谨慎选择患者。
局限性
- 对所有非复杂性病例常规使用TEVAR目前仍有争议,因存在卒中和脊髓缺血等风险。
- 正在进行的随机对照试验(包括IMPROVE-AD、SUNDAY和EARNEST)有望提供关键数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type B aortic dissection (TBAD) presents a complex clinical challenge requiring coordinated, multidisciplinary care to optimize patient outcomes. While rapid intervention is crucial for complicated TBAD, the optimal management of uncomplicated cases remains less well-defined. Historically, uncomplicated TBAD was managed medically, but recent years have seen a shift toward selective interventional approaches. Updated American and European guidelines now recommend thoracic endovascular aortic repair (TEVAR) for high-risk, uncomplicated cases, characterized by factors including a large aortic diameter, large entry tears, or persistent pain. Observations from the International Registry of Acute Aortic Dissection highlight a significant shift toward endovascular management and reduced mortality over time. The acute dissection stentgraft or best medical treatment and investigation of stent grafts in aortic dissection trials suggested that pre-emptive TEVAR may benefit certain high-risk patients by promoting favorable aortic remodeling. However, routine use of TEVAR in all uncomplicated cases is presently still controversial due to risks such as stroke and spinal cord ischemia, which emphasize the importance of careful patient selection. Current evidence supports a tailored approach that integrates clinical and imaging risk factors to identify patients most likely to benefit from pre-emptive TEVAR. In addition, ongoing randomized controlled trials, including IMPROVE-AD, SUNDAY, and EARNEST, will hopefully provide critical data on the risks and benefits of TEVAR in uncomplicated TBAD. Moving forward, interdisciplinary collaboration among different medical and engineering specialties, and refined risk stratification will be essential to advance TBAD management, enhancing outcomes for both complicated and uncomplicated cases.
引用
- de Kort JF, Hasami NA, Been M, et al. Trends and Updates in the Management and Outcomes of Acute Uncomplicated Type B Aortic Dissection. Ann Vasc Surg. 2025. PMID: 39855380. doi:10.1016/j.avsg.2024.12.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。